Drug Profile
Diclofenac/tramadol - AbbVie
Latest Information Update: 21 Apr 2015
Price :
$50
*
At a glance
- Originator Abbott Laboratories
- Developer AbbVie
- Class Antirheumatics; Cyclohexanols; Dimethylamines; Nonsteroidal anti-inflammatories; Opioid analgesics; Phenylacetates; Small molecules
- Mechanism of Action Cyclooxygenase inhibitors; Opioid mu receptor agonists; Serotonin uptake inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Pain
Most Recent Events
- 21 Apr 2015 No recent reports of development identified - Phase-III for Pain in India (PO)
- 02 Jan 2013 Abbott spins out its pharmaceuticals business to new company called AbbVie
- 12 Oct 2010 Phase-III clinical trials in Pain in India (PO)